



CURVEBEAMAI AGM PRESENTATION

27 November 2025



DISCLAIMER

Introduction

THIS PRESENTATION IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA OR TO ANY RESIDENT THEREOF, OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION IS UNLAWFUL. THIS DOCUMENT IS NOT, AND DOES NOT CONSTITUTE, AN OFFER OR INVITATION TO SUBSCRIBE FOR, BUY OR SELL SECURITIES IN ANY JURISDICTION. BY ACCEPTING, ACCESSING OR REVIEWING THIS PRESENTATION, YOU ACKNOWLEDGE AND AGREE TO THE TERMS SET OUT BELOW.

This presentation has been prepared by CurveBeam AI Limited (ACN 140 706 618) (**CurveBeam** or the **Company**) and contains summary information about CurveBeam and the business conducted by it as at 26th November 2025. The information in this presentation is for informational purposes only, does not purport to be complete and is not a prospectus, product disclosure statement or other offering document for the purposes of Chapter 6D or Part 7.9 of the Corporations Act 2001 (Cth) (**Act**) or the law of any other jurisdiction. It should be read in conjunction with CurveBeam's other periodic and continuous disclosure announcements, including its full year results for the period ended 30 June 2025, lodged with the ASX on 28 August 2025 available from the Australian Securities Exchange ("ASX") at www.asx.com.au.

As further detailed below, none of CurveBeam, nor its advisers (**Advisers**) nor their respective affiliates, related bodies corporate (as defined in the Act) or security holders and their respective directors, officers, employees, partners, representatives, consultants, agents or advisers (each a **Limited Party** and together, the **Limited Parties**) guarantees, recommends, or makes any representation or warranty to, or takes responsibility for, the accuracy, reliability or completeness of the information contained in this presentation or the Company's securities, including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it. To the maximum extent permitted by law, each Limited Party disclaims any liability for any loss arising from the use of or reliance on such information including as to the accuracy or completeness of the information, statements, opinions or matters, express or implied, contained in, arising out of or derived from, or for omissions from, this presentation.

Not an offer or financial product advice

The information contained in this presentation is for informational purposes only and should not be considered, and does not contain or purport to contain, an offer, invitation, solicitation or recommendation with respect to the subscription, purchase or sale of any securities in CurveBeam nor does it constitute legal, taxation, financial product or investment advice. The general information in this presentation has been prepared without taking into account the investment objectives, financial situation or particular needs of any particular person. Recipients of the presentation must undertake their own independent investigations, consideration and evaluation. Neither this presentation nor any of its contents will form the basis of any contract or commitment and it is not intended to induce or solicit any person to engage in any transaction nor is it intended to be used as the basis for making an investment decision. CurveBeam recommends that potential investors consult their professional advisors as an investment in CurveBeam is subject to investment and other known and unknown risks, some of which are beyond the control of CurveBeam or its directors and therefore any investment is considered to be speculative in nature.

Forward looking statements

The information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of CurveBeam's views on future performance or condition. Past performance cannot be relied upon as an indicator of future performance. This presentation contains certain forward-looking statements. The words "forecast", "estimate", "like", "anticipate", "opinion", "should", "could", "may" and other similar expressions are intended to identify future earnings, financial position and performance of CurveBeam. You are cautioned not to place undue reliance on these statements. These forward-looking statements are based on estimates, projections and assumptions made by CurveBeam about circumstances and events that have not yet taken place. Although due care and attention has been used in the preparation of these statements, such forward-looking statements are based on numerous assumptions regarding CurveBeam's present and future business strategies and the political, regulatory and economic environment in which CurveBeam will operate in the future and are subject to change without notice. Statements about market and industry trends, which are based on interpretations of current market conditions, may not be reasonable, and are not guarantees or predictions of future performance.


The actual results or performance of CurveBeam may be materially different from the results or performance expressed or implied by such forward-looking statements. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including any of the Limited Parties). No representation, warranty or assurance (express or implied) is given that the occurrence of the events expressed or implied in any forward-looking statement in this presentation will actually occur). Subject to any continuing obligations under applicable law, the Company expressly disclaims any obligation or undertaking to provide any updates or revisions to any forward-looking statements in this presentation to reflect any change in expectations in relation to any forward-looking statement or any change in events, conditions or circumstances on which any statement is based.

The distribution of this Presentation in jurisdictions outside Australia may be restricted by law and you should observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. In particular, this Presentation may not be distributed or released in the United States. The entitlements and the New Shares have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended ("**U.S. Securities Act**"), or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold, directly or indirectly, in the United States, unless they have been registered under the U.S. Securities Act (which CurveBeam has no obligation to do or procure) or are offered or sold in a transaction exempt from, or not subject to, the registration requirements of the U.S. Securities Act and any other applicable U.S. state securities laws. Refer to the Appendix of this Presentation for further details about international offer restrictions

Financial information

All numbers in this presentation are stated in Australian dollars (**A\$**) unless stated otherwise.

Share Price Performance



Institutional shareholding

~50%


Directors, Employees & Related Parties

~27%

CVB AGM - FY25 KEY HIGHLIGHTS

- CurveBeam AI
 - FY2024 Revenue was ~\$6.5m AUD
 - FY 2025 Revenue was ~\$12.1m AUD
 - **Revenue growth of around ~ 86%** increase in sales YoY
 - FY24 loss from ordinary activities ~ \$23m AUD
 - FY25 Loss from ordinary activities ~ \$16.8m AUD
 - **Loss from activities reduced by ~ 30%**
- **FDA clearance for the enhanced HiRise™** was achieved July of 2024
 - A major development program to enhance the HiRise™ to process robotic system cut guides
 - Technical hurdles met and passed for imaging requirements
 - Presently doing the verification/validation for a labelling change to the CT reading protocol to show standing v lying down are equivalent in maintaining robot cut guide accuracy
- **China Strategy –\$10million milestone-based strategic** investment through a JV with Wego Orthopedics – designed to reduce the company reliance on one robotic system for sales – delivers a second shot on goal to reach breakeven revenues
- Raising (ANREO & Placement) **completed in Q1 FY25 of A\$11.54m**
- The **expansion of the Stryker agreement** in FY25 to include Stryker Australia/NZ
- **Vendor Financing Facility** – signed an agreement with an international financing partner for a facility of **approximately A\$18 million** (€10 million).

CHINA STRATEGY



TARGETED STRATEGIC BENEFITS

- ✓ Capital Injection with Reduced Dilution - A\$10m at 40.5 cents – milestone based
- ✓ A new path to target material sales/profit – linked with Wego surgical Robot using WBCT
- ✓ China will be initially supplied US HiRise™ – NMPA targeting H2 CY 2026
- ✓ Facilitates rapid entry into one of the world's largest & fastest-growing medical device markets
- ✓ Commercial Validation of CVB products while targeting to address pricing/GP requirements

CHINA MANUFACTURING

- ✓ Once China manufactured device is MNPA approved - business changes to royalty payments
- ✓ Volume-based manufacturing should deliver lower costs & greater margins (outside US)
- ✓ Accelerated Innovation – enables more cost effective & faster design, development, & commercialisation of next-generation imaging devices
- ✓ Meets the requirement of Volume Based Procurement (VBP) in the Chinese state system
- ✓ Dual-factory strategy (China & US) reduces supply chain risk
- ✓ Reduces US-tariff related risks and allows options to manage
- ✓ Opens up global market access to markets we presently cannot access due to costs

Note: Re-approval from China FDA will be required for the China Manufactured HiRise system

Source - https://english.www.gov.cn/english.www.gov.cn/news/202411/30/content_WS674a493ac6d0868f4e8ed8a9.html



China Agreements


Key terms

Share Subscription Agreement & Voluntary Escrow Deed

- **Equity Investment** - The Partner will make an equity investment of up to A\$10 million in CVB as follows:
 - Execution of license agreements A\$4 million milestone payment.
 - HiRise™ sold generating ~A\$4.6 million in sales - plus A\$1 million milestone payment.
 - HiRise™ sold generating ~A\$18.5 million in sales – plus A\$2 million milestone payment.
 - Regulatory (NMPA) A\$1m & next generation WBCT release milestones totalling A\$3m.
- The shares will be issued at \$0.405. If all milestones are met, total shares are expected to be approximately 5% of CVB's current issued share capital.
- **Escrow Provisions** - Each tranche of shares issued will be held subject to voluntary escrow for 24 months in accordance with market-standard terms, to align the Partner's interests with the long-term success of the collaboration.

Common Provisions Across All Agreements

- **Non-compete** - Partner agrees not to manufacture or distribute competing products, without the prior consent of CVB.
- **Ten Year Term** - The IP Licence Agreement, Manufacturing Licence Agreement & Distribution Agreement operate for an initial term of ten (10) years.
- **Governing law & dispute resolution** - The Licence Agreements are governed by the laws of Singapore. The Share Subscription and Escrow Deed are governed by the laws of Australia.
- **Arbitration** - Disputes are to be referred to mediation followed by arbitration in Singapore.



HiRise™

InReach™


Discontinued



pedCAT®

FY24 TO FY25 CUMMULATIVE PURCHASE ORDERS ANALYSIS

Purchase Orders - US & Rest of World - Financial Year to Date



ENHANCED HIRISE™ VALIDATION IN KNEE/HIP


Validation ongoing with multiple suppliers of knee products

- CVB is **currently working to validate** HiRise™ for multiple knee suppliers for non-robotic surgery
 - 1) Restor3d/Conformis, 2) Medacta Knee Osteotomy PSI^{1,3}, 3) Newclip - knee Osteotomy PSI¹
- CVB is focused on a specific robotic validation. It is the market leading system & the only system, in the top four (85% of the market), that requires CT scans. HiRise™ validation is expected to increase sales as
 - It lowers CT pre-authorization hurdles with payers, & is supported by a co-pay in reimbursement
 - CT scans are done today by referring to radiology for a routine multidetector CT (supine)
 - A HiRise™ scan validation, is expected to improve workflow & improve surgeon office imaging revenue

Summary & update on validation

1. The Company is pleased with the increased engagement from the vendor of a major robotic system for the validation of the enhanced HiRise™
2. CVB has conducted several meetings, including a system demonstration with the vendor R&D team, during Q1FY26 demonstrating the latest scanning procedure & the new upgraded movement mitigation mechanism
3. Discussions have been constructive & continue – positive feedback on new movement mitigation methods
4. Please note that **the process is an internal one to the vendor's organisation**, subject to their judgment, and their priorities. We are working closely with the vendor to resolve our position in the list

What is a robotic cut guide



What is a motion rod

 **During the scan, the pelvis, leg, and Motion Rod must remain motionless.**

1. Position patient supine, feet first with foot secured in an upright position with a rolled towel or blanket wrapped around the bottom of the foot to secure the ankle as shown.  Figure 2.
2. Elevate the knee of the patient slightly with a rolled towel or blanket.
3. Wrap the velcro strap one complete revolution around the rod as shown in Figure 2. Do this for both Velcro straps, one at the hip position and one at the ankle position as shown.
4. Set the Motion Rod on the patient to pass from just proximal of Hip Center to distal of Ankle Center as shown in Figure 3.
5. Adjust the femoral and tibial straps to secure the rod.
6. Verify the rod is in both anterior/posterior and medial/lateral field of views for all scan regions.


 **The velcro strap must be wrapped around the rod in one complete revolution, before wrapping around the leg. Straps should be snug, but not excessively tight.**

3. CONSIDERATIONS

- Scan patient anytime before procedure (up to 8 weeks in advance)
- Ensure the patient is comfortable and relaxed. This is critical for achieving a motionless scan
- If metallic components are present in the operative leg, it may not be possible to obtain an image of significant quality to support a procedure. If metal components are present in the non-operative leg (e.g. knee components), attempt to isolate the non-operative leg from the scan region.  Figure 3.


ROBOTIC MARKET DYNAMICS – DRIVES DEPENDENCE

1. Robotic system adoption for orthopedics continues at a steady pace with ~ 25% of US operating rooms having access to a robot - Source Global Data 2023
2. Stryker **MAKO**, J&J **VELYS**, Zimmer **ROSA** and S&N **CORI** – held 85% of the market - Source Global Data 2023
3. Stryker has the dominant position with 2000 placements by the end of 2024 – Source Gabelli Funds 2025




BMD SAAS MDCT MODULE UPDATE

Multidetector CT (MDCT)



HiRise



- As presented in the quarterly activity report for Q1 FY 25, the Company's revised BMD regulatory strategy is to clear the first BMD module on multidetector CT (MDCT) scanners, the primary technology used today.
- This strategic shift enables earlier access to modest SaaS revenues from existing acute-care trauma settings, an initial application for rapid BMD results from MDCT scans in the U.S. market.
- The file remains on a 510(k) class II pathway, but additional comparison with BMD obtained from Dual energy X-ray (DXA) was requested by the FDA.
- All additional clinical data has been collated and processed in September 25.
- The file has been held up to ensure the required data management platform is verified and validated as part of the original filing (not serial). The DMP is a key component to offer an automated BMD as a SaaS based MDCT product.
- The file submission to the FDA is for November 2025. The Company remain on a target for FDA clearance for H1 CY26.
- A Special 510K is targeted to file post this first MDCT FDA clearance to deliver an FDA cleared BMD SaaS for the HiRise™.

WBCT COMPETITORS – UPDATE

PlanMed Verity

- Available today – FDA, CE, TGA
- Partial foot, Ankle, knee
- Unilateral and not natural bilateral weight bearing
- Difficult for elderly to access – must pull full weight onto affected joint
- To do the knee, contralateral limb approaches a perpendicular position



Large MDCT scanner – not suited for group surgeon settings



Canon Aquilion RISE



SinoVision

PlanMed XFI – WBCT – in development/future competition

- US FDA clearance announced
- Space & height limits access in group surgeon settings
- No automated multiple Dx bone fragility solution – CBAI IP protected

